Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasal Spray NST-4G in Recurrent Glioblastoma
NCT03275558Phase 1Withdrawn
- Sponsor
- Center Trials & Treatment
- Start
- Jul 2018
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of axitinib, sunitinib and pazopanib in glioblastoma (GBM), Gliosarcoma (GS) and anaplastic glioma, sponsored by Center Trials & Treatment. Primary endpoint: Progression-Free Survival at 48 months. Planned start Jul 2018; status: withdrawn.
02
Drugs
axitinibsunitinibpazopanib
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)anaplastic glioma
Beyond the preview
Go deeper on NCT03275558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03275558.